By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Enterprise Replace Part 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is at the moment evaluating MN-166 (ibudilast) in a Part 3 scientific trial for amyotrophic lateral sclerosis (ALS). The trial initiated in 2019 and, if profitable, outcomes from this trial are anticipated to assist … Read more
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Stable money & equivalents place as former CFO resumes position… Oramed Prescription drugs (NASDAQ:ORMP) has named its former Chief Monetary Officer to the CFO place once more. In June 2024, the corporate named Avraham Gabay as CFO, Secretary and Treasurer to interchange former CFO David … Read more
By Thomas Kerr, CFA NASDAQ:HTCR READ THE FULL HTCR RESEARCH REPORT On August 14, 2024, HeartCore (NASDAQ:HTCR) reported 2nd quarter 2024 monetary outcomes which confirmed revenues beneath expectations regardless of 20% natural development within the core software program enterprise. Revenues within the quarter have been $4.1 million in comparison with $5.1 million within the 2nd … Read more
Though many different promotional channels have entered the market, social media stays the primary selection of selling consultants and companies to have interaction shoppers. Owing to its distinctive potential and massive variety of customers, you’ll get unbelievable advantages from selling your model on social networks. It turns into extra necessary when you’ve gotten a lately … Read more
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Monetary Replace On August 8, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced monetary outcomes for the second quarter of 2024. The corporate recorded the primary revenues for XOLREMDI following its industrial launch in April 2024. Income within the second quarter of 2024 totaled $0.6 … Read more
